Theriva Biologics, Inc. TOVX 深 滬
已收盤 05-08 16:00:00 美东时间
0.354
-0.006
-1.67%
華盛通- 最 高0.357
- 今 開0.357
- 成交量 123.67万股
- 最 低 0.343
- 昨 收 0.36
- 總市值 1624.60万
- 52周最高 0.8632
- 市盈率 靜 --
- 換手率 2.69%
- 52周最低 0.1628
- 委 比 -33.33%
- 總股本 4589.27万
- 歷史最高 37800.00
- 量 比 0.29
- 振 幅 3.89%
- 歷史最低 0.1628
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theriva Biologics Q1 EPS $(0.05), Inline
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 96.77 percent increase over losses of $(1.55) per share from the same period last year.
05-06 04:47
Why Is Theriva Stock Gaining Monday?
Theriva Biologics Inc. shares are trading higher Monday after announcing upcoming poster on VIRAGE phase 2b VCN-01 pancreatic cancer trial.
04-20 22:05
Theriva Biologics' VCN-01 Shows Immune-Mediated Activity And Improved Outcomes Across Subgroups In Phase 2b Pancreatic Cancer Trial At AACR 2026
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple
04-18 04:08
Theriva Biologics Faces Delays in Warrant Approval Meeting
An update from Theriva Biologics ( ($TOVX) ) is now available. On April 9, 2026...
04-10 04:52
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target
Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and announces $1 price target.
04-01 04:57
Theriva Biologics Announces It Receives FDA's General Agreement For Phase 3 Clinical Study Of VCN-01 To Treat Metastatic Pancreatic Adenocarcinoma
Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a
03-23 20:06
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics announced successful outcomes from a Type B End-of-Phase 2 meeting with the FDA, enabling advancement into a proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). FDA feedback aligns with previous scientific advice from the EMA, finalizing the pivotal Phase 3 trial protocol. The trial will include repeat dosing ...
03-23 12:00
Theriva Biologics GAAP EPS of -$2.08
Theriva Biologics press release (TOVX): FY GAAP EPS of -$2.08. Cash and cash equivalents totaled $13.1 million as of December 31, 2025, compared to $11.6 million as of December 31, 2024. The Company’s...
03-13 03:12
